Lara Meisner - Jan 23, 2023 Form 4 Insider Report for Viridian Therapeutics, Inc.\DE (VRDN)

Role
General Counsel and Secretary
Signature
/s/ Kristian Humer, Attorney-in-Fact for Lara Meisner
Stock symbol
VRDN
Transactions as of
Jan 23, 2023
Transactions value $
-$103,331
Form type
4
Date filed
1/25/2023, 05:04 PM
Previous filing
Dec 22, 2022
Next filing
Feb 10, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRDN Common Stock Options Exercise $114K +4.97K $23.03 4.97K Jan 23, 2023 Direct
transaction VRDN Common Stock Options Exercise $26.2K +1.87K +37.66% $14.00 6.84K Jan 23, 2023 Direct
transaction VRDN Common Stock Sale -$244K -6.84K -100% $35.66 0 Jan 23, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VRDN Stock Option (Right to Buy) Options Exercise $0 -4.97K -11.12% $0.00 39.8K Jan 23, 2023 Common Stock 4.97K $23.03 Direct F2
transaction VRDN Stock Option (Right to Buy) Options Exercise $0 -1.87K -8.56% $0.00 20K Jan 23, 2023 Common Stock 1.87K $14.00 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $35.22 to $36.06. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
F2 The option vested 25% on December 2, 2021 and then in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date.
F3 The option vested 25% on September 22, 2022 and then in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date.